The Latest Cardiac and Vascular News
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer (“CEO”) and Chairperson of the Board of Directors of the Company, effective December 13, […]
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration (FDA) Pivotal IDE study of Adagio’s VT Cryoablation System. Procedures were performed by […]
August 19, 2024 04:01 PM Eastern Daylight Time LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. “For years there has been underinvestment in and pent-up demand for innovation in ablation […]
July 31, 2024 04:01 PM Eastern Daylight Time LAGUNA HILLS, Calif. & NEW YORK–(BUSINESS WIRE)–Adagio Medical, Inc. (“Adagio Medical”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD; or “ARYA IV”), […]
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration […]
LAGUNA HILLS, Calif., March 25, 2024 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced CE Mark approval of its ultra-low temperature cryoablation (“ULTC”) system for the treatment of monomorphic ventricular tachycardia. The system consists of the upgraded cryoablation console, […]
LAGUNA HILLS, Calif., Sept. 14, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the first ultra-low temperature cryoablation (ULTC) procedure performed using the Adagio vCLAS™ catheter system in the United States as part of the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation for Recurring Monomorphic Ventricular Tachycardia) clinical trial, NCT # […]
LAGUNA HILLS, Calif., May 3, 2023 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the completion of enrollment in its Cryocure-VT trial (NCT # 04893317) of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic ventricular tachycardias. 60 patients […]
LAGUNA HILLS, Calif. , Oct. 24, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced its first pulsed field cryoablation (PFCA) procedure performed using the Adagio CryoPulse™ catheter system as part of the PARALELL (Pulsed Field Ablation and Pulsed Field CRyoAbLation […]
LAGUNA HILLS, Calif., July 28, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology […]
